COVID antibody study in kids halted after just 7 participants

NCT ID NCT04992273

Terminated Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tested a single shot of two lab-made antibodies (casirivimab and imdevimab) in children under 12 who are at high risk for severe COVID-19. The goal was to measure how long the antibodies stay in the blood and check for side effects. Only 7 children took part before the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID - 19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Advanced Research Center, Inc

Anaheim, California, 92805, United States
Batchelor's Children's Research Institute

Miami, Florida, 33136, United States
Coastal Pediatric Research

Charleston, South Carolina, 29414, United States
Jacobi Medical Center

The Bronx, New York, 10461, United States
Regeneron Research Site

Richmond, Virginia, 23226, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States
Stony Brook University Hospital

Stony Brook, New York, 11794, United States

Conditions

Explore the condition pages connected to this study.

COVID - 19